key: cord-0709032-6vlo2w4g
authors: Afzal, Adeel
title: Molecular diagnostic technologies for COVID-19: Limitations and challenges
date: 2020-08-06
journal: J Adv Res
DOI: 10.1016/j.jare.2020.08.002
sha: 78e15b13069582aaa0bdd27aa8523235d37258b1
doc_id: 709032
cord_uid: 6vlo2w4g

To curb the spread of COVID-19 (coronavirus disease 2019) pandemic, the world needs diagnostic systems capable of rapid detection and quantification of the novel coronavirus (SARS-CoV-2). Many biomedical companies are rising to the challenge and developing COVID-19 diagnostics. In the last few months, some of these diagnostics have become commercially available for healthcare workers and clinical laboratories. However, the diagnostic technologies have specific limitations and reported several false-positive and false-negative cases, especially during the early stages of infection. Currently, more sophisticated and reliable molecular diagnostics are being developed to improve the COVID-19 diagnosis. This article presents an overview of the commercial and pre-commercial molecular diagnostics to address several questions and issues related to the limitations of current technologies and future research and development challenges to enable timely, rapid, low-cost, and accurate diagnosis of emerging infectious diseases.

The last decade has witnessed the rise of epidemics and pandemics such as 2012's coronavirus disease (MERS, middle-eastern respiratory syndrome) in the Middle East [1] , 2014's Ebola virus disease (EVD, formerly known as Ebola hemorrhagic fever) in West Africa [2] , 2015's zika virus disease in Latin America [3] , and 2019's coronavirus disease in Wuhan, China [4] . These emerging infectious diseases pose a grave threat to human health and the global economy. Lately, the novel coronavirus (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2) aggressively spread throughout the world causing the COVID-19 pandemic [5] . As of 29 th July 2020, 185 of 197 UN countries are affected by this pandemic and despite all containment efforts, the number of COVID-19 infected people is rising above 16.5 million with over 655 thousand deaths accounting for the global fatality rate of ~ 3.96% [6, 7] . For COVID-19, the mean incubation period and the mean serial interval are 5.2 days (95% CI: 4.1-7.0 days) and 7.5 days (95% CI: 5.3-19.0 days), respectively; while the basic reproduction number (R 0 ) is reported to be 2.2 (95% CI: 1.4-3.9), i.e. a SARS-CoV-2 carrier can spread it to ~ 2.2 persons on average [8] . Therefore, to limit the spread of SARS-CoV-2 and overcome the COVID-19 crises it is important to identify the suspected individuals and isolate them, which requires indefatigable diagnostic testing.

The dependable diagnostic solutions have been immediately developed and marketed to help early diagnosis of COVID-19 [9] [10] [11] . Thus far, two types of diagnostic tests have been commercialized: one, molecular diagnostics that detect part of the viral genome (i.e. RNA) in the respiratory tract specimens; and second, serological or antibody tests that detect SARS-CoV-2 specific antibodies in serum specimens [10] . Molecular diagnostics are used to identify symptomatic or asymptomatic SARS-CoV-2 carriers, and the basic performance criterion for these tests is high clinical sensitivity to avoid false-negative results. On the other hand, the objective of serological tests is to identify individuals with an active immune response to the SARS-CoV-2 antigen, and the basic performance criterion for these tests is high clinical specificity to rule out false-positive results.

Sethuraman et al. [12] published a timeline for the detection of viral RNA (molecular diagnosis) and immune-response antibodies (serological diagnosis), which revealed that molecular diagnostics could identify infected individuals a week before the onset of symptoms while antibodies could only be detected ≥ 8 days after the symptoms appear. Therefore, molecular diagnostics are essentially the only tests for early diagnosis of COVID-19 [13] .

This article aims to present a critical performance analysis of commercially available molecular diagnostics and review major factors influencing their diagnostic performance. The criteria for the selection of molecular diagnostic tests is two-fold: (a) only those tests are selected that have been approved by major healthcare authorities around the world, and (b) most importantly, those molecular diagnostic kits are shortlisted that have been independently tested by WHO or relevant healthcare authorities for their clinical sensitivity and specificity.

At present, molecular techniques based on the real-time (quantitative) reverse transcriptasepolymerase chain reaction (RT-PCR) are considered the gold standard for COVID-19 diagnosis [14, 15] . Real-time RT-PCR detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates. A typical RT-PCR test can take 4-6 hours from sample to result [10] .

However, RT-PCR has proven to be extremely handy in clinical settings to consistently perform a large number of tests. As of 29 th July 2020, more than 260 million COVID-19 tests have been performed in the most impacted countries worldwide [16] . Besides, other molecular diagnostic approaches, for instance, loop-mediated isothermal amplification (LAMP) [17] , and clustered regularly interspaced short palindromic repeats (CRISPR) [18] are being developed for COVID-19 detection.

Herein, a performance-based review of the commercial and pre-commercial molecular diagnostics is presented. The clinical performance data reported by the manufacturers of commercially available tests are compared with the clinical evaluations performed by independent research labs and healthcare organizations, and the results are reviewed to define upcoming research and development challenges. Since the understanding of molecular diagnostics for COVID-19 is still evolving, their limitations in the current pandemic scenario are deliberated to ask forthcoming research questions that would improve the diagnostic technologies for COVID-19 and future emerging infectious diseases.

SARS-CoV-2 is a betacoronavirus (β-CoV) that is structurally similar to other coronaviruses (SARS-CoV and MERS-CoV) from the Coronaviridae family [19] . It has a positive-sense, single-stranded RNA (+ssRNA) enclosed in nucleocapsid (N) protein, while envelop (E), membrane (M), and spike (S) proteins form its outer shell or viral envelop (Figure 1a ). The trimeric spike glycoprotein is responsible for interaction with the host cells (Figure 1b) [20] [21] [22] . Wrapp et al. [23] determined the structure of the spike protein by cryoelectron microscopy. In its predominant conformation, the spike protein exhibits strong binding with host cell's angiotensin-converting enzyme 2 (ACE2) receptors through one of its receptor-binding domains (RBD) (Figure 1b) [23, 24] . The viral genome (RNA) is ~ 30,000 nucleotides long comprising a structural gene unit that encodes S, E, M, and N proteins and two large, open reading frame genes (ORF1a and ORF1b) that encrypt sixteen non-structural proteins (NSP) including RNA-dependent RNA polymerase (RdRp) (Figure 1c ) [25, 26] .

The findings of high-throughput genomic sequencing of SARS-CoV-2 are regularly deposited on the global initiative on sharing all influenza data (GISAID) [27] . The development of oligonucleotides (primers and probes) for molecular diagnosis of COVID-19 was initiated as soon as these findings were made public on 10 th Jan 2020 [9, 27] . CDC (USA), China CDC, Charité Germany, Institut Pasteur (France), NIID Japan, Hong Kong University, and NIH Thailand researchers developed forward/reverse primers and probes for real-time RT-PCR-based molecular diagnostics (Figure 1c ).

They also published comprehensive protocols for the detection of SARS-CoV-2, which can be found on the WHO's website [28] . Thanks to these research and development efforts, the first test kits were available for clinical diagnosis of the disease by 4 th Feb 2020 [29] . Since then, several molecular diagnostic kits have been commercialized for the detection of the SARS-CoV-2 genome. These diagnostics are approved for emergency use in the current pandemic situation by major healthcare authorities worldwide.

Real-time RT-PCR is the major workhorse in the field of molecular diagnostics. It has been extensively used for high-throughput screening and early diagnosis of COVID-19, and other infectious diseases in the past. RT-PCR can amplify and detect a single copy of the specific genomic sequence and therefore, it is extremely sensitive [30] . Furthermore, real-time RT-PCT is a quantitative technique as the number of copies of RNA generated in a PCR increases exponentially and is proportional to the amount of starting material, i.e. viral load [31] . At the moment, a vast majority of the commercially available technologies (tests) for early diagnosis of COVID-19 are based on realtime RT-PCR assays [32] . Figure 2 shows the principle of a real-time RT-PCR diagnostic. In principle, real-time RT-PCR is used to transcribe and amplify the specific SARS-CoV-2 genomic sequence(s).

For this purpose, viral RNA is first extracted from the biological specimen collected from the nasal or nasopharyngeal swabs and is purified. Purified RNA template is converted into a cDNA principle [34, 35] .

During amplification, the fluorescence signals are detected in real-time and the fluorescence emission data is plotted against the replication cycles ( Figure 2) . A fluorescent signal threshold is decided by the standard deviation of the average baseline fluorescence of cycles 3-15 [31] , whereas the cycle threshold (Ct) is determined by the number of PCR cycles needed to report a detectable fluorescence, i.e. greater than the fluorescent signal threshold. Therefore, a lower Ct value implies the presence of a greater viral RNA load [12] . In general, for diagnosis of COVID-19 infection, Ct < 40 is considered clinically positive. China CDC recommends a Ct value of 37, i.e. a suspect is judged clinically positive if Ct is <37 [36] . A Ct value of >40 is considered clinically negative, while it is recommended to repeat the test if Ct is 37-40 [36] .

Commercially available real-time RT-PCR diagnostics for COVID-19 are either one-step or twostep assays. One-step RT-PCR kit utilizes a single tube and buffer for RT and PCR steps, while in a two-step RT-PCR assay RT and PCR are performed separately in different tubes with independently optimized buffers. One-step RT-PCR assays are high-speed, reproducible, and suitable for high-throughput diagnosis of COVID-19 because they require limited sample management and reduce the risk of cross-contamination and human errors [37] . Two-step RT-PCR assays, on the other hand, are generally more flexible and tunable and offer superior sensitivity and low detection limit [38] .

To improve the diagnostic efficiency, duplex or multiplex real-time RT-PCR test kits are developed, which enable the simultaneous detection of two or more specific sequences, thereby improving the diagnostic sensitivity and reliability. For instance, FDA-approved Abbott's RealTime SARS-CoV-2 assay is a dual target RT-PCR assay for the quantitative recognition of RdRp and N genes. It uses an unrelated RNA sequence as an internal control (IC) to validate the PCR, and detects the RdRp, N, and IC target sequences via specific fluorescent-labeled probes. Different fluorophores are used for SARS-CoV-2-specific and IC-specific probes to allow simultaneous detection of these targets. Abbott's RealTime SARS-CoV-2 assay uses the viral RNA extracted from the nasal or nasopharyngeal swab samples. Rutgers Clinical Genomics Laboratory developed an RT-PCR assay that utilizes self-collected saliva samples for COVID-19 diagnosis. The assay is commercialized as TaqPath™ COVID-19 Combo Kit by Life Technologies (a part of Thermo Fisher Scientific, Inc.), and simultaneously detects ORF1ab, N, and S genes. The test not only offers painless and quick sample collection, high volume testing, and lower exposure risk to healthcare personnel, but higher clinical sensitivity and clinical specificity [39] .

An overview of the clinical performance in terms of time-to-result, clinical sensitivity (PPA), clinical specificity (NPA), and limit of detection (LoD) of various commercial and pre-commercial molecular diagnostics is presented in Table 1 . Thus far, 336 commercially available or pre-commercial (under development) molecular assays for COVID-19 diagnosis are submitted to the Foundation for Innovative New Diagnostics (FIND), which is WHO's collaborating center for laboratory strengthening and diagnostic technology evaluation [40] . However, a majority of these tests are not evaluated yet and/or are not approved by the WHO for emergency use. This review presents only selected commercial or pre-commercial diagnostics (Table 1) , which are already approved by major healthcare authorities around the world and have been independently evaluated [41] [42] [43] [44] [45] [46] [47] [48] .

The most important criterion for a commercial molecular diagnostic is its clinical sensitivity (PPA) and LoD to accurately diagnose COVID-19 at an early stage of infection and to avoid false-negative results. Understandably, during a pandemic of this scale, the standards for authorization of these diagnostics are relaxed to afford the availability of test kits and large-scale screening of the samples. Direct RT-PCR Kit, and Roche's cobas ® SARS-CoV-2 Test. They demonstrated that all tests were equally specific, but Cepheid's Xpert Xpress had higher sensitivity and lower LoD. However, the outcomes were limited by the small sample size (20-26 specimens), they concluded that due to low Ct ranges, the minor sensitivity differences might not have a significant impact on the diagnostic performance during clinical practice [41] . The clinical specificity of these RT-PCR tests was 100%, which meant the design of primers was specific to the genomic sequences of SARS-CoV-2. Moore et al. [51] compared the diagnostic performance of Abbott's RealTime SARS-CoV-2 and ID NOW™ COVID-19 diagnostics. The later utilizes isothermal amplification and has a fast turnaround time of <13 min [11] . RealTime SARS-CoV-2 assay takes a longer time, but it is more sensitive and reliable compared to ID Now TM COVID-19 [51] .

A comparison of seven commercially available RT-PCR diagnostic kits from different manufacturers revealed ≥96% efficiency for the detection of low concentrations of SARS-CoV-2 RNA in clinical samples [52] . Compared to the in-house E gene PCR test (Ct ≤ 34.5), the positive samples were successfully identified by these kits with slight variations in Ct values and overall performance ( Figure 3) . No crossreactivity to other CoVs was observed and all kits demonstrated 100% specificity [52] . Wang et al. [53] high LoD value (7744 copies/mL), which was attributed to the technical deficiencies in the product's design that might include reagent instability and inappropriate ratios, irrational oligonucleotide design for primer or probe, and impurities [53] .

Other molecular diagnostic technologies based on LAMP and CRISPR mechanisms are evolving at a rapid pace [54] [55] [56] [57] . However, many of these diagnostics have not been approved by the healthcare authorities worldwide or have not been independently assessed yet. Atila BioSystems' iAMP COVID-19 Detection Kit uses isothermal amplification (LAMP) is approved for emergency use by FDA and reports 100% sensitivity, low LoD (~4 copies/µL), and 1-hour sample-to-result time [58] .

Also, the Sherlock TM CRISPR SARS-CoV-2 kit is the first and only CRISPR-based diagnostic approved for emergency use by the FDA. It performs quantitative SARS-CoV-2 detection within 1 hour with 100% specificity and low LoD (6.75 copies/µL) [59] . Further development and independent assessment of these technologies would provide alternative molecular diagnostic solutions that are faster and suitable for high-throughput screening of suspected individuals.

Molecular diagnostics can be developed rapidly and provide extremely sensitive, specific, and often quantitative detection of the SARS-CoV-2 RNA. However, they are complex, expensive, and slow to deliver. A single RT-PCR test kit may cost over 100 USD, while setting up a diagnostic/processing lab requires more than 15,000 USD, whereas the analysis time is 4-6 hours, and sample-to-result turnaround time is more than 24 hours [10, 60] . Furthermore, the molecular diagnostics are not deliverable to end-users and are intended only for qualified clinical laboratory personnel and mediumor high-complexity laboratories. Yet, some studies suggest a high false-negative rate of RT-PCR diagnostics for COVID-19 [61] [62] [63] . Erroneous RT-PCR results may be caused by inappropriate 

For commercial diagnostics, the samples are usually collected from upper and lower respiratory specimens such as nasal, nasopharyngeal, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage fluid, and nasopharyngeal wash/aspirate or nasal aspirate.

However, the biodistribution of virus particles may vary in different specimens [65] . Wang et al. [66] collected 1070 specimens from 205 COVID-19 patients to investigate the biodistribution of SARS-CoV-2 and concluded that the highest positive rates of 93% (14/15) > 69% (72/104) > 62% (5/8) > 32% (126/398) were observed for bronchoalveolar lavage fluid, sputum, nasal swabs, and pharyngeal swabs, respectively. The average Ct was lowest for nasal swabs (Ct = 24.3; 1.4 × 10 6 copies/mL) that indicated the highest viral loads. In a similar study, the samples collected from 52 suspected COVID-19 patients exhibited a higher positive rate for sputum (77%; 40/52) compared to throat swabs (44%; 23/52) [67] . To et al. [68, 69] suggest the highest positive rates of 92% (11/12) for saliva specimens from deep throat. It is suggested that deep throat saliva sampling may offer early detection of SARS-CoV-2 [70] . However, these studies are not conclusive because the number of samples is not uniform or is very small in certain cases. Furthermore, false-negatives may occur due to inappropriate sample collection time reference to the onset of symptoms or technical deficiencies in sampling methods [12] .

Therefore, an RT-PCR result must be validated by the detailed knowledge of the symptoms and epidemiological history, and clinical examination. Moreover, there is a need to perform systematic research and careful analysis with a larger and more diverse sample size to find conclusive evidence of the biodistribution of SARS-CoV-2 in the body.

The knowledge of the detectable SARS-CoV-2 load in the respiratory tract during different stages of infection is still evolving [71] . The viral load kinetics also varies from person to person and depends on several factors including the patients' epidemiological history, immune response, and treatment or medication effects [72] . Therefore, the timing of the diagnosis is one of the most important limiting factors for molecular diagnostics. Inappropriate diagnostic timing may lead to false-negative results, especially at an early stage of infection [73, 74] . A recent study shows that the highest pharyngeal shedding of SARS-CoV-2 is in the first few days of symptoms and peaks on day 4 with 7.11 × 10 8 gene equivalents per throat swab, while sputum viral shedding lasted till the sixth week, i.e. end of symptoms [75] . Sethuraman et al. [12] established the diagnostic timeline for RT-PCR tests. It is possible to detect SARS-CoV-2 RNA in nasopharyngeal swab specimens one week before the onset of symptoms as well as in the prodromal phase when the initial symptoms such as malaise, fatigue, fever, and dry cough appear [76, 77] . Therefore, according to the suggested diagnostic timeline [12] , nasal or nasopharyngeal swabs specimens stand for early diagnosis of oligosymptomatic or presymptomatic individuals with an epidemiological history, whereas sputum samples should be analyzed to configure complete recovery and avoid false-negative results.

As discussed in the previous section, the clinical sensitivity (PPA) and LoD of an RT-PCR diagnostic play a major role in the early diagnosis of COVID-19. High PPA and very low LoD of the test are desirable to prevent false-negative results. Although multiple factors influence the outcomes of a test, technical deficiencies in the product's design such as unstable reagents, inappropriate amounts, irrational oligonucleotide design, and impurities should be avoided [53] . Besides, certain primers and probe designs are inherently more sensitive compared to others [78] [79] [80] . For instance, the primer-probe sets for CDC's N1 and N2 genes have different PPA and LoD with N2 variants showing much lower LoD (356 copies/mL) compared to N1 assay (779 copies/mL). Nalla et al. [81] compared the sensitivity of different RT-PCR primer-probe sets (RdRp/E genes by Charité Germany [82] , and N1/N2 genes by CDC, as shown in Figure 1c ). They discovered E-gene by Charité Germany and N2-gene by CDC were the most sensitive assays [81] . The comparison studies reveal high specificity and no cross-sensitivity for different assays as well as comparable sensitivities except RdRp assay by Charité Germany that was least sensitive likely because of a deficiency in the reverse primer [12] .

Owing to its rapid pandemic-scale spread of SARS-CoV-2, it shows very high genomic diversity in gene position and nucleotide sequences [83, 84] . The outcomes of the genomic sequencing of SARS-CoV-2 are regularly shared on the GISAID database [27] . Pachetti et al. [85] performed an analysis of 220 SARS-CoV-2 genomic sequences placed on GISAID and found eight novel recurrent genomic mutations, which suggested that SARS-CoV-2 was evolving and different strains of SARS-CoV-2 might coexist. The evolution of SARS-CoV-2 and genetic diversity present a colossal new challenge to molecular diagnostic manufacturers. Osório and Correia-Neves [86] analyzed 1825 high-coverage genomic sequences from the GASAID database. Their analysis revealed that ~79% (26/33) primer binding sequences in at least one gene used in RT-PCR were mutated compared to Wuhan-Hu-1 (NC_045512) [86] . Therefore, they concluded that 14% of SARS-CoV-2 variants were not detectable with at least one of the commercialized primers. Consequently, the manufacturers need to regularly optimize the oligonucleotides through frequent analysis of the updated genomic sequences on GASAID to enhance their accuracy and reliability.

The modern molecular diagnostics are not intended for point-of-care diagnosis of COVID-19 but provide a core diagnostic solution to conduct large numbers of tests in a reasonable timeframe [87] .

Li et al. [88] estimated that 80% of the COVID-19 positive cases were initially transmitted by the undetected infections during the early stages of this pandemic. Therefore, accurate diagnosis of the disease is crucial to curb its spread. In the current pandemic situation, the SARS-CoV-2 tests were rapidly developed and approved for emergency use. Rationally, due to the lack of research and development time, the commercialized diagnostics were not validated or optimized with sufficient numbers of clinical samples, which might have led to inaccurate results [53] . Furthermore, falsenegative results may have been caused by inadequate diagnostic timing, low sensitivity, or low viral load. Therefore, it is plausible that infected individuals may have been missed by the real-time RT-PCR tests [89] [90] [91] . In a recent study, Liu et al. [92] indicated that RT-PCR results were potentially erratic, and clinical diagnosis of symptomatic individuals or those with epidemiological history should not rely on RT-PCR only. Ideally, RT-PCR must be combined with clinical examination and computed tomography (CT) to medically judge the suspected individuals [93, 94] . Considering these deficiencies and limitations, continuous optimization of RT-PCR diagnostics is critical to meet the diagnostic standards. In this view, digital RT-PCR technology may enhance the accuracy, sensitivity, and lower detection limits thereby enabling accurate and early diagnosis of COVID-19 [95] .

Apart from the aforementioned research and development challenges, the diagnostic efficiency of modern RT-PCR tests is also influenced by the lack of organized knowledge and the novelty of the disease. Thus far, a majority of the research reported in recent literature is rendered with severe limitations. For example, the sample size is not enough to establish convincing conclusions and certain patients have been treated with different medications after different intervals of the onset of symptoms for which the effects on SARS-CoV-2 population, replication, immunity, and efficacy are still unknown [41, 72, 75] . Therefore, on the research front, more structured and systematic pilot studies need to be performed to generate concrete knowledge about the perseverance of SARS-CoV-2 in specific anatomic sites at different times before and after the onset of symptoms.

Furthermore, there is a portentous need to monitor, analyze, and regularly update the data about genetic mutations and evolution of SARS-CoV-2 in different communities worldwide. The knowledge progress in these areas will help optimize the molecular diagnostics and relevant protocols. human errors. However, these systems have low sensitivity compared to conventional real-time RT-PCR and exhibit high LoD, i.e. 2 × 10 4 copies/mL for ID NOW TM test [45] and 9 × 10 3 copies/mL for Lumex Microchip [96] . Nonetheless, these innovations may help point-of-care diagnosis in remote locations, especially in third-world countries where setting up numerous medium or high-complexity laboratories is not possible. Soon, the development of new techniques may improve the quality of compact and deliverable diagnostic solutions.

Presently, molecular diagnostics combined with a comprehensive clinical examination of suspected asymptomatic or oligosymptomatic individuals may reduce the number of false-negative results. However, an independent and careful assessment of the commercial diagnostic tests should be conducted to identify diagnostic errors and determine the efficiency of approved tests [97] . These approaches would lead to better understand and diagnose COVID-19 and improve the future epidemic readiness for emerging infectious diseases. 

Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study

Emergence of Zaire Ebola virus disease in Guinea

Zika Virus Outbreak

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

World Health Organization W. Coronavirus disease 2019 (COVID-19): situation report

COVID-19) Dashboard. World Health Organ

TrackCorona -COVID-19 Tracker and Live Map

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Coronavirus and the race to distribute reliable diagnostics

Fast, portable tests come online to curb coronavirus pandemic

Companies are racing to develop COVID-19 tests for the US. Will the tests help?

Interpreting Diagnostic Tests for SARS-CoV-2

The Promise and Peril of Antibody Testing for COVID-19

Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Recent advances and perspectives of nucleic acid detection for coronavirus

COVID-19 tests by country: Number of coronavirus (COVID-19) tests performed in the most impacted countries worldwide as of

Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-effective diagnostic method for infectious diseases

Underappreciated uses in perinatology

A Novel Coronavirus from Patients with Pneumonia in China

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

The Architecture of SARS-CoV-2 Transcriptome

The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms

Global Initiative on Sharing All Influenza Data

COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans

Emergency Use Authorization of in vitro Diagnostic Products. US Food Drug Adm

Pathogenic viruses: Molecular detection and characterization

Basic principles of real-time quantitative PCR

Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2

Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase

Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer

Allelic discrimination by nick-translation PCR with fluorogenic probes

Viral Disease Control Institute. China CDC 2020

Assay Techniques and Test Development for COVID-19 Diagnosis

Two-Step Versus One-Step RNA-to-CT TM 2-Step and One-Step RNA-to-CT TM 1-Step: Validity, Sensitivity, and Efficiency

New Rutgers saliva test for coronavirus gets FDA approval 2020

FIND. SARS-CoV-2 diagnostic pipeline. Found Innov New Diagn FIND 2020

Comparison of Commercially Available and Laboratory Developed Assays for in vitro Detection of SARS-CoV-2 in Clinical Laboratories

SARS-CoV-2 Mise à jour le 20/05/20. Société Fr Microbiol 2020

FIND: Diagnostics resource centre. FIND 2020

Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test

Clinical Evaluation of Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2

COVID-19) CE IVD: genesig® Real-Time PCR assay

Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic

Laboratory Diagnosis of COVID-19: Current Issues and Challenges

Do we know the diagnostic properties of the tests used in COVID-19? A rapid review of recently published literature

Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV RT-PCR assay for the detection of SARS-CoV-2

Comparison of seven commercial RT-PCR diagnostic kits for COVID-19

Limits of Detection of Six Approved RT-PCR Kits for the Novel SARS-coronavirus-2 (SARS-CoV-2)

Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay

Rapid colorimetric detection of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic plat-form: iLACO

CRISPR-Cas12-based detection of SARS-CoV-2

Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. Infectious Diseases (except HIV/AIDS)

Atila Biosystems: iAMP COVID-19 Detection Kit

The Sherlock TM CRISPR SARS-CoV-2 kit. Sherlock Biosci 2020

Test, re-test, re-test': using inaccurate tests to greatly increase the accuracy of COVID-19 testing

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in

Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens

Comparison of sputum and nasopharyngeal swabs for detection of respiratory viruses

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia

Consistent Detection of 2019 Novel Coronavirus in Saliva

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs

Real-time RT-PCR in COVID-19 detection: issues affecting the results

Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review

Virological assessment of hospitalized patients with COVID-2019

Imaging changes in patients with 2019-nCov

Anosmia and Ageusia as Initial or Unique Symptoms after SARS-COV-2 Virus Infection

Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens

Comparison of SARS-CoV2 N gene real-time RT-PCR targets and commercially available mastermixes

An assessment of real-time RT-PCR kits for SARS-CoV-2 detection

Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Genetic diversity and evolution of SARS-CoV-2

Genomic Diversity of Severe Acute Respiratory Syndrome-Coronavirus 2 in Patients With Coronavirus Disease

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays

Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)

Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests

False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence

SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge

Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

The indispensable role of chest CT in the detection of coronavirus disease 2019 (COVID-19)

SARS-CoV-2 detection using digital PCR for COVID-19 diagnosis, treatment monitoring and criteria for discharge

SARS-CoV-2) Detection System. Lumex Instrum -Lab Anal Equip Manuf

Diagnostic Testing for the Novel Coronavirus

AA extends his appreciation to the Deanship of Scientific Research, University of Hafr Al Batin for funding this work through the research group project number G-107-2020.

The author declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The author has declared no conflict of interest.

Adeel Afzal